U.S. Hospitality Stock News

NYSE:CCI
NYSE:CCISpecialized REITs

Is Crown Castle (CCI) Offering Value After Short Term Rebound And Multi Year Slump

If you are wondering whether Crown Castle stock is priced attractively right now, the recent mix of short term gains and longer term weakness makes the valuation story especially interesting. The share price closed at US$89.10, with returns of 3.4% over 7 days and 5.1% over 30 days. Year to date the stock is up 0.5%, but down 12.3% over 1 year, 10.2% over 3 years and 38.1% over 5 years. Recent headlines have focused on Crown Castle's position within U.S. telecom infrastructure and how...
NYSE:RCUS
NYSE:RCUSBiotechs

Is It Too Late To Consider Arcus Biosciences (RCUS) After Its 221% One Year Surge?

If you are wondering whether Arcus Biosciences is reasonably priced or getting ahead of itself, the current share price invites a closer look at what investors may actually be paying for. The stock last closed at US$26.06, with returns of 5.1% over the past 7 days, 13.5% over 30 days, 11.9% year to date, and 220.9% over the last year, which points to a stock that has already seen significant movement. Recent coverage around Arcus Biosciences has focused on its position in the biotech space...
NYSE:RBLX
NYSE:RBLXEntertainment

Roblox Taps Sunil Rao To Turn India Growth Into Monetization

Roblox (NYSE:RBLX) has appointed Sunil Rao as Managing Director for India. Rao is tasked with leading local strategy and supporting growth in one of Roblox's fastest expanding international markets. This is Roblox's first direct senior leadership hire in India, focused on expanding the creator ecosystem and user base. Roblox runs a user generated content gaming and social platform where players and creators interact through virtual worlds. As global gaming, social interaction and digital...
NasdaqGS:COLL
NasdaqGS:COLLPharmaceuticals

What Collegium Pharmaceutical (COLL)'s Margin Pressure Ahead of Q1 2026 Earnings Means For Shareholders

Collegium Pharmaceutical, a specialty pain-medicine maker, is approaching its first-quarter 2026 earnings release on May 7, with Wall Street expecting earnings per share of US$1.52 amid recent downward estimate revisions. Investors are increasingly focused on the company’s shrinking adjusted operating margin and relatively small revenue base, which together raise questions about the durability of future profits. We’ll now examine how concerns about Collegium’s weakening operating margin...
NYSE:PBI
NYSE:PBICommercial Services

A Look At Pitney Bowes (PBI) Valuation After Mixed Q1 2026 Earnings And Raised Revenue Guidance

Pitney Bowes (PBI) has drawn fresh attention after first quarter 2026 earnings showed revenue of US$477.41 million, lower than a year earlier, alongside higher net income and raised full year revenue guidance. See our latest analysis for Pitney Bowes. The earnings release appears to have been a key catalyst, with the stock’s 30-day share price return of 40.89% and year to date share price return of 50.44% building on a very large 3-year total shareholder return. However, the 7-day share price...
NYSE:NJR
NYSE:NJRGas Utilities

New Jersey Resources (NJR) Margin Compression Tests Clean Energy Growth Narrative In Q2 2026 Results

New Jersey Resources (NJR) has just reported its Q2 2026 results, with Q1 fiscal 2026 revenue at US$604.9 million and EPS of US$1.22 setting the tone for how the year is shaping up for the utility. Over the past few quarters, revenue has ranged from US$298.9 million to US$913.0 million while EPS has moved between a loss of US$0.15 and a high of US$2.04. This gives a clear sense of how earnings and the top line have tracked across different periods. With trailing net margin at 15.2% and the...
NYSE:LUV
NYSE:LUVAirlines

The Bull Case For Southwest Airlines (LUV) Could Change Following Spirit Rescue Fares And Legal Payout

In late April 2026, Southwest Airlines began offering discounted fares and A-List status matches to travelers stranded by Spirit Airlines’ shutdown, while also concluding a long-running legal dispute by paying US$946,102.87 in damages to former flight attendant Charlene Carter. This combination of opportunistic customer outreach to Spirit passengers and the resolution of a nearly decade-long legal case could influence how investors weigh Southwest’s growth opportunities against its legal and...
NYSE:MC
NYSE:MCCapital Markets

Moelis (MC) Is Down 8.9% After Earnings Dip And Capital Returns Update Has The Bull Case Changed?

Moelis & Company recently reported first-quarter 2026 net income of US$38.43 million, down from US$50.27 million a year earlier, while also confirming a quarterly dividend of US$0.65 per share payable on June 18, 2026. Alongside these results, Moelis completed two share repurchase tranches totaling nearly US$53.64 million and filed a US$38.70 million employee stock ownership plan-related shelf registration for Class A common stock, highlighting an active approach to capital returns and...
NYSE:MGM
NYSE:MGMHospitality

Is MGM Resorts (MGM) Attractive After A 20.7% Year Gain And Recent Pullback?

Wondering if MGM Resorts International at around US$37.91 is a bargain or already pricing in the story? This article walks through what the current valuation signals might mean for you. The stock is up 20.7% over the last year, with returns of 3.9% year to date and 3.4% over the last month. However, the most recent week saw a 4.6% decline. Recent headlines around MGM Resorts International have focused on the company as a key player in US leisure and entertainment, with investors weighing how...
NasdaqGS:UPST
NasdaqGS:UPSTConsumer Finance

Is It Time To Reconsider Upstart Holdings (UPST) After Recent Share Price Swings?

If you are wondering whether Upstart Holdings at around US$31.17 is priced for a comeback or still carrying too much risk, the starting point is to understand what the current market value really reflects. The stock has been volatile, with a 5.1% decline over the last 7 days, a 21.9% gain over the last 30 days, a 32.0% decline year to date, and a 39.4% decline over the last year. The 3-year return sits at 121.2%, and the 5-year return at a 65.1% decline. Recent coverage around Upstart often...
NasdaqGS:CYTK
NasdaqGS:CYTKBiotechs

Assessing Cytokinetics (CYTK) Valuation After Recent Share Price Momentum

Why Cytokinetics Stock Is Back on Investors’ Radar Cytokinetics (CYTK) has climbed recently, with the stock up 16.7% over the past day and 27% over the past week, prompting investors to reassess what is currently priced into this biopharmaceutical story. See our latest analysis for Cytokinetics. Today’s share price of $77.09 sits against a 1-year total shareholder return of 126.9% and a 5-year total shareholder return of about 3.2x. Recent double digit share price gains suggest momentum has...
NYSE:CAH
NYSE:CAHHealthcare

Should Dividend Hike And Buybacks Amid Impairment Charges Require Action From Cardinal Health (CAH) Investors?

Cardinal Health reported past third-quarter 2026 results showing higher sales of US$60,940 million but lower net income of US$399 million, alongside a pre-tax goodwill impairment of US$184 million in its Navista & ION unit and completion of a US$1.73 billion share repurchase program. The Board’s decision to raise the quarterly dividend to US$0.5158 per share, even as earnings softened and impairments were taken, underscores management’s confidence in cash generation and the ongoing shift...
NYSE:PRGO
NYSE:PRGOPharmaceuticals

Infant Formula Probes And ESOP Share Filing Might Change The Case For Investing In Perrigo (PRGO)

Perrigo Company plc recently filed a US$94.19 million shelf registration for 8,269,649 ordinary shares related to its employee stock ownership plan and affirmed a quarterly dividend of US$0.29 per share payable on June 16, 2026. At the same time, Perrigo is contending with legal scrutiny and operational issues in its infant formula business, including a securities lawsuit, investigations into potential fiduciary breaches, and remediation costs that have weighed on analyst expectations for...
NasdaqGS:CHRD
NasdaqGS:CHRDOil and Gas

A Look At Chord Energy (CHRD) Valuation As Q1 Results And Strong Momentum Approach

Chord Energy (CHRD) heads into its Q1 report with the market watching for 3% year on year revenue growth and earnings of $3.49 per share, against a backdrop of firmer crude pricing. See our latest analysis for Chord Energy. Chord Energy's share price has climbed strongly in recent months, with a 47.46% 3 month share price return and 57.54% year to date, while the 1 year total shareholder return sits at 73.28%. This signals strong momentum as investors reassess growth prospects and risk. If...
NYSE:TDAY
NYSE:TDAYMedia

The Bull Case For USA TODAY (TDAY) Could Change Following Q1 Profit Rebound On Digital And AI Deals

In the first quarter of 2026, USA TODAY Co., Inc. reported revenue of US$548.49 million, down from US$571.57 million a year earlier, while turning a prior net loss of US$7.33 million into net income of US$19.89 million. The company credited improved profitability to growing digital revenue, AI-related licensing deals, and subscription gains, and reiterated full-year 2026 guidance calling for flat to slightly lower revenue but higher net income compared with last year. Next, we will examine...
NasdaqGS:CNOB
NasdaqGS:CNOBBanks

A Look At ConnectOne Bancorp (CNOB) Valuation After Strong Q1 Earnings And Dividend Increase

Q1 earnings and dividend move draw fresh attention to ConnectOne Bancorp stock ConnectOne Bancorp (CNOB) just reported first quarter results with higher net interest income, net income and earnings per share versus a year ago, alongside an 8.3% increase in its quarterly common dividend. See our latest analysis for ConnectOne Bancorp. At a share price of $30.08, ConnectOne Bancorp has a 30 day share price return of 11.28% and a year to date share price return of 15.16%, alongside a 1 year...
NasdaqGM:NTLA
NasdaqGM:NTLABiotechs

ARK Invest’s NTLA Buy Puts Dilution And CRISPR Progress In Focus

ARK Invest recently acquired over 3 million Intellia Therapeutics shares, worth more than US$43 million. The purchase reflects increased institutional interest in Intellia Therapeutics, which trades under ticker NasdaqGM:NTLA. This transaction follows earlier coverage that focused on Intellia's clinical programs, regulatory updates, and financial position. Intellia Therapeutics focuses on CRISPR/Cas9-based therapeutics, an area that many investors watch closely as gene editing moves from...